[Federal Register Volume 64, Number 34 (Monday, February 22, 1999)]
[Notices]
[Pages 8584-8585]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-4306]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Transformation Associated 
Recombination (TAR) System in Yeast for Specific Cloning of DNAs as 
Yeast Artificial Chromosomes (YACs)

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
International Application PCT/US96/11478 and USPA SN 09/060,023 (CIP of 
the above), titled ``Transformation Associated Recombination (TAR) 
System in Yeast for Specific Cloning of DNAs as Yeast Artificial 
Chromosomes (YACs)'' to Genaissance Pharmaceuticals, Inc., having a 
place of business in New Haven, Connecticut. The United States of 
America is an assignee of the patent rights in this invention.


[[Page 8585]]


DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before May 24, 
1999 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: L. Manja R. Blazer, Ph.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 496-7056, ext. 224; Facsimile: (301) 402-0220; e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: The TAR system enables the isolation of 
specific families of genes, individual genes and chromosome fragments 
as linear or circular YACs. The system provides enrichments that are 
orders of magnitude higher over previous reports. The circular YACs 
provide special opportunities for isolation and transfer of cloned 
material to other organisms. The system includes cloning with and 
without a yeast origin of replication on the TAR cloning vectors to 
assure opportunities to clone a wide range of DNAs.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7 
and may be limited to the field of use of providing genomics services 
to alliance partners. The method and materials of this invention would 
be available from the NIH to third party organizations for internal 
research purposes. The prospective exclusive license may be granted 
unless, within 90 days from the date of this published Notice, NIH 
receives a written evidence and argument that establishes that the 
grant of the license would not be consistent with the requirements of 
35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: February 11, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 99-4306 Filed 2-19-99; 8:45 am]
BILLING CODE 4140-01-M